Fig. 7

Silencing CAV2, PHLDA1, and VDAC3 separately significantly increases sensitivity to cisplatin. A–C qRT-PCR and Western blot showing CAV2, PHLDA1, and VDAC3 knockdown 48 and 72 h after transfection with CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs. D: cytotoxicity curves of the LUAD cell lines A549, PC9 and ESCC cell line TE1 transfected with nontargeting (ctrl) or CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs and treated for 48 h with different concentrations of cisplatin (0, 2.5, 5, 10, 20, 40 μM). E EdU for A549, PC9 and TE1 transfected with nontargeting (ctrl) or CAV2-targeting, PHLDA1-targeting and VDAC3-targeting siRNAs and treated for 48 h with cisplatin (10 μM)